Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Influenza - Page 11

Influenza

Celdara Medical secured SBIR funding to develop an adjuvanted universal flu vaccine
Biotechnology | Infectious Disease | Influenza | NIH | Vaccine

Celdara Medical secured SBIR funding to develop an adjuvanted universal flu vaccine

On Nov. 17, 2020, Celdara Medical announced that the National Institute of Allergy and Infectious Disease (NIAID) of…

Read More Celdara Medical secured SBIR funding to develop an adjuvanted universal flu vaccineContinue

Aegis Sciences launched combined test for SARS-CoV-2 and influenza A/B virus
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

Aegis Sciences launched combined test for SARS-CoV-2 and influenza A/B virus

On Nov. 16, 2020, Aegis Sciences announced that it had launched a combined test for SARS-CoV-2 and influenza…

Read More Aegis Sciences launched combined test for SARS-CoV-2 and influenza A/B virusContinue

CHMP recommended EU approval of Roche’s Xofluza (baloxavir marboxil) for the treatment of influenza
Biotechnology | Infectious Disease | Influenza | Therapeutics

CHMP recommended EU approval of Roche’s Xofluza (baloxavir marboxil) for the treatment of influenza

On Nov. 13, 2020, Roche announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…

Read More CHMP recommended EU approval of Roche’s Xofluza (baloxavir marboxil) for the treatment of influenzaContinue

Mesa Biotech received additional $13 million from HHS to develop 30 minute SARS-CoV-2 & Flu A/Flu B test
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

Mesa Biotech received additional $13 million from HHS to develop 30 minute SARS-CoV-2 & Flu A/Flu B test

On Nov. 6, 2020, Mesa Biotech announced it had been awarded a contract up to $13 million from…

Read More Mesa Biotech received additional $13 million from HHS to develop 30 minute SARS-CoV-2 & Flu A/Flu B testContinue

Novavax announced facility expansion to support global vaccine development
Biotechnology | COVID-19 | Infectious Disease | Influenza | Vaccine

Novavax announced facility expansion to support global vaccine development

On Nov. 2, 2020, Novavax announced the expansion of its Maryland campus to accommodate the company’s rapid growth…

Read More Novavax announced facility expansion to support global vaccine developmentContinue

PerkinElmer received CE Mark for multi-analyte respiratory panel including COVID-19
Biotechnology | COVID-19 | Diagnostics | Disease | Infectious Disease | Influenza

PerkinElmer received CE Mark for multi-analyte respiratory panel including COVID-19

On Oct. 26, 2020, PerkinElmer announced that its PKamp Respiratory SARS-CoV-2 RT-PCR Panel had received clearance to be…

Read More PerkinElmer received CE Mark for multi-analyte respiratory panel including COVID-19Continue

CerTest Biotec and BD announced CE Mark for combination COVID-19, Influenza, RSV test
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

CerTest Biotec and BD announced CE Mark for combination COVID-19, Influenza, RSV test

On Oct. 21, 2020, CerTest Biotec, along with BD (Becton, Dickinson), announced that the VIASURE SARS-CoV-2 (N1 +…

Read More CerTest Biotec and BD announced CE Mark for combination COVID-19, Influenza, RSV testContinue

OPKO Health’s BioReference Laboratories launched multiplex COVID-19 and influenza A/B test
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

OPKO Health’s BioReference Laboratories launched multiplex COVID-19 and influenza A/B test

On Oct. 20, 2020, BioReference Laboratories, an OPKO Health company, announced that it was accepting specimens for a…

Read More OPKO Health’s BioReference Laboratories launched multiplex COVID-19 and influenza A/B testContinue

University of Oxford scientists developed extremely rapid diagnostic test for Covid-19
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

University of Oxford scientists developed extremely rapid diagnostic test for Covid-19

On Oct. 15, 2020, scientists from the University of Oxford’s Department of Physics announced they had developed an…

Read More University of Oxford scientists developed extremely rapid diagnostic test for Covid-19Continue

Sonic Healthcare enhanced test offerings with launch of multiplex assay for COVID-19 and flu
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza | Medical Device

Sonic Healthcare enhanced test offerings with launch of multiplex assay for COVID-19 and flu

On Oct. 7, 2020, Sonic Healthcare USA announced that it had launched a multiplex RT-PCR assay that combined…

Read More Sonic Healthcare enhanced test offerings with launch of multiplex assay for COVID-19 and fluContinue

Vaxxas announced $22 million award from U.S. Government to advance Vaxxas Needle-Free HD-MAP vaccine patch
Biotechnology | Infectious Disease | Influenza | Vaccine

Vaxxas announced $22 million award from U.S. Government to advance Vaxxas Needle-Free HD-MAP vaccine patch

On Oct. 5, 2020, Vaxxas announced a $22 million United States government award to support the deployment of…

Read More Vaxxas announced $22 million award from U.S. Government to advance Vaxxas Needle-Free HD-MAP vaccine patchContinue

Quidel received Emergency Authorization for rapid antigen ‘ABC test’ assay for Influenza A+B and COVID-19
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

Quidel received Emergency Authorization for rapid antigen ‘ABC test’ assay for Influenza A+B and COVID-19

On Oct. 2, 2020, Quidel announced that it had received Emergency Use Authorization from the U.S. Food and…

Read More Quidel received Emergency Authorization for rapid antigen ‘ABC test’ assay for Influenza A+B and COVID-19Continue

Quest Diagnostics launched three new combined COVID-19 and respiratory virus tests
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

Quest Diagnostics launched three new combined COVID-19 and respiratory virus tests

On Sept. 30, 2020, Quest Diagnostics announced three different test options for healthcare providers across the U.S.to aid…

Read More Quest Diagnostics launched three new combined COVID-19 and respiratory virus testsContinue

BD announced CE Mark of portable, rapid point-of-care antigen test to detect SARS-CoV-2 in 15 minutes
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

BD announced CE Mark of portable, rapid point-of-care antigen test to detect SARS-CoV-2 in 15 minutes

On Sept. 30, 2020, BD (Becton, Dickinson) announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the…

Read More BD announced CE Mark of portable, rapid point-of-care antigen test to detect SARS-CoV-2 in 15 minutesContinue

XBiotech to develop human antibody combination as candidate treatment for influenza-COVID-19 co-infection
Biotechnology | COVID-19 | Infectious Disease | Influenza | Therapeutics

XBiotech to develop human antibody combination as candidate treatment for influenza-COVID-19 co-infection

On Sept. 21, 2020, XBiotech announced it was developing a new breakthrough candidate therapy it calls FLUVID for…

Read More XBiotech to develop human antibody combination as candidate treatment for influenza-COVID-19 co-infectionContinue

Sanofi and GSK confirmed agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Influenza | Vaccine

Sanofi and GSK confirmed agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccine

On Sept. 18, 2020, Sanofi and GSK finalised and signed an advanced purchase agreement with the European Commission…

Read More Sanofi and GSK confirmed agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccineContinue

Vaxess Technologies to develop Coronavirus + Influenza Combo Patch Vaccine in Partnership with Medigen
Biotechnology | COVID-19 | Infectious Disease | Influenza | NIH | Vaccine

Vaxess Technologies to develop Coronavirus + Influenza Combo Patch Vaccine in Partnership with Medigen

On Sept. 15, 2020, Vaxess Technologies and Medigen Vaccine Biologics (MBV) announced a partnership to develop a combined…

Read More Vaxess Technologies to develop Coronavirus + Influenza Combo Patch Vaccine in Partnership with MedigenContinue

Flu may increase the spread of Covid-19
COVID-19 | Infectious Disease | Influenza | Non-Profit Research | Vaccine

Flu may increase the spread of Covid-19

On Sept. 14, 2020, scientists at the Max Planck Institute for Infection Biology in Berlin and the Institut…

Read More Flu may increase the spread of Covid-19Continue

The ACIP updated flu vaccine recommendations for 2020-2021
Biotechnology | CDC | Infectious Disease | Influenza | Vaccine

The ACIP updated flu vaccine recommendations for 2020-2021

On Sept. 9, 2020, the American Academy of Family Physicians (AAFP) reviewed and agreed with the Advisory Committee…

Read More The ACIP updated flu vaccine recommendations for 2020-2021Continue

LabCorp launched first combined test for Covid-19, flu and RSV in time for flu season
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

LabCorp launched first combined test for Covid-19, flu and RSV in time for flu season

On Sept. 8, 2020, LabCorp announced the launch of the first testing method to simultaneously detect COVID-19, influenza…

Read More LabCorp launched first combined test for Covid-19, flu and RSV in time for flu seasonContinue

DiaSorin Molecular received FDA clearance for the Simplexa Flu A/B & RSV Direct Gen II Assay
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

DiaSorin Molecular received FDA clearance for the Simplexa Flu A/B & RSV Direct Gen II Assay

On Sept. 7, 2020, DiaSorin Molecular announced that it had received U.S. Food and Drug Administration (FDA) Clearance…

Read More DiaSorin Molecular received FDA clearance for the Simplexa Flu A/B & RSV Direct Gen II AssayContinue

Sanofi and GSK initiated Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
Biotechnology | COVID-19 | Infectious Disease | Influenza | Vaccine

Sanofi and GSK initiated Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate

On Sept. 3, 2020, Sanofi and GSK announced the start of the Phase 1/2 clinical trial for their…

Read More Sanofi and GSK initiated Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidateContinue

U.S. Government exercised option to purchase additional RAPIVAB from BioCryst for delivery to Strategic National Stockpile
Biotechnology | CDC | Infectious Disease | Influenza | NIH | Therapeutics

U.S. Government exercised option to purchase additional RAPIVAB from BioCryst for delivery to Strategic National Stockpile

On Sept. 3, 2020, BioCryst Pharmaceuticals announced that the U.S. Department of Health and Human Services (HHS) had…

Read More U.S. Government exercised option to purchase additional RAPIVAB from BioCryst for delivery to Strategic National StockpileContinue

Roche received FDA Emergency Use Authorization for the cobas SARS-CoV-2 & influenza A/B test for use on cobas 6800/8800 systems
Biotechnology | COVID-19 | Diagnostics | FDA | Infectious Disease | Influenza

Roche received FDA Emergency Use Authorization for the cobas SARS-CoV-2 & influenza A/B test for use on cobas 6800/8800 systems

On Sept. 3, 2020, Roche announced that the cobas SARS-CoV-2 & Influenza A/B Test for use on the…

Read More Roche received FDA Emergency Use Authorization for the cobas SARS-CoV-2 & influenza A/B test for use on cobas 6800/8800 systemsContinue

Janssen discontinued Pimodivir influenza development program
Biotechnology | Infectious Disease | Influenza | Therapeutics

Janssen discontinued Pimodivir influenza development program

On Sept. 2, 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that it had made a…

Read More Janssen discontinued Pimodivir influenza development programContinue

NIH awarded MicroGEM $409 million to fast-track rapid, no-lab COVID-19 saliva test
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza | NIH

NIH awarded MicroGEM $409 million to fast-track rapid, no-lab COVID-19 saliva test

On Sept. 2, 2020, MicroGEM announced it had been awarded up to $40.9 million by the National Institutes…

Read More NIH awarded MicroGEM $409 million to fast-track rapid, no-lab COVID-19 saliva testContinue

CDC published ACIP 2020-21 influenza vaccination recommendations
Influenza | Life Science History

CDC published ACIP 2020-21 influenza vaccination recommendations

On Aug. 21, 2020, the CDC published Immunization Practices Advisory Committee (ACIP) 2020-21 influenza vaccination recommendations. Routine annual…

Read More CDC published ACIP 2020-21 influenza vaccination recommendationsContinue

Celdara Medical announced receipt of NIH funding for pandemic influenza antiviral development
Biotechnology | COVID-19 | Influenza | NIH

Celdara Medical announced receipt of NIH funding for pandemic influenza antiviral development

On Aug. 12, 2020, Celdara Medical announced that the NIH had awarded a Small Business Innovation Research (SBIR)…

Read More Celdara Medical announced receipt of NIH funding for pandemic influenza antiviral developmentContinue

Sanofi and GSK announced discussions with EU to supply up to 300 million doses of COVID-19 vaccine
Biotechnology | COVID-19 | Influenza

Sanofi and GSK announced discussions with EU to supply up to 300 million doses of COVID-19 vaccine

On Jul. 31, 2020, Sanofi and GSK announced advanced discussions, with the European Commission for the supply of…

Read More Sanofi and GSK announced discussions with EU to supply up to 300 million doses of COVID-19 vaccineContinue

Seqirus began shipping 2020/21 influenza vaccines to U.S. market
Biotechnology | Infectious Disease | Influenza | Vaccine

Seqirus began shipping 2020/21 influenza vaccines to U.S. market

On Jul. 30, 2020, Seqirus announced it had begun shipping its portfolio of seasonal influenza vaccines to customers…

Read More Seqirus began shipping 2020/21 influenza vaccines to U.S. marketContinue

Page navigation

Previous PagePrevious 1 … 9 10 11 12 13 … 24 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search